Roche RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Susvimo (ranibizumab injection). The regulatory body approved the drug Susvimo for the treatment of ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blin ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the ...

Susvimo can help people with diabetic retinopathy (DR) maintain their vision and prevent progression to blindness with only one treatment every nine monthsSusvimo's innovative technology via the Port ...

Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the failure, noting positive details and vowing to seek FDA approval ...

standardized eye chart at 24 weeks, compared to 10.8 letters in the control group, a statistically significant benefit of 3.4 letters (p=0.0107). Compared to Lucentis monotherapy, OPT-302 (2.0 mg ...

Lucentis (ranibizumab) is a brand-name eye injection that’s prescribed for certain eye conditions in adults. As with other drugs, Lucentis can cause side effects, such as eye pain or irritation.

Lucentis (ranibizumab) is a prescription drug that’s used for eye conditions such as macular edema. Lucentis comes as a liquid solution that’s given by injection into the eye. Lucentis is ...

AMD is an eye disease that can blur a patient's central ... on exactly when the company will launch its biosimilar version of Lucentis in South Korea. While an official from Chong Kun Dang said ...

KHN analyzed the top 30 prescribers of the macular degeneration eye drugs Avastin and Lucentis in 2019 through a Centers for Medicare & Medicaid Services database. Private equity companies went on ...

Biogen Inc. BIIB and privately-held Samsung Bioepis announced that the FDA has approved their biosimilar, Byooviz (ranibizumab-nuna) referencing Roche’s RHHBY eye drug, Lucentis (ranibizumab).